Paper

Effects of Sodium-Glucose Cotransporter-2 Inhibitor Use on Major Adverse Cardiovascular Events in Participants With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease Treated With Tirzepatide Versus Dulaglutide (SURPASS-CVOT)

Diabetologie und Stoffwechsel · 2026 · David A. D’Alessio, Russell J. Wiese, H Nishiyama et al.